Publications: https://orcid.org/0000-0003-1214-9665

Preprints

  1. Environment-Dependent Modes of Adaptive Evolution in Neuroblastoma: Plasticity as a Selectable Trait. Cecilia Roux, Sian Hamer, Abigail Shea, Emilia Chen, Ayeh Sadat Sadr, Christie English, Alejandro Allo Anido, Harvey Che, Birgit Geoerger, Louis Chesler, Gudrun Schleiermacher, Michael David Morgan, Alejandra Bruna. bioRxiv (2023, revised in 2024).12.07.570359; doi: https://doi.org/10.1101/2023.12.07.570359

  2. The Role of Phenotypic Plasticity in Adaptation to Treatment and Prospective Plasticity Drivers in Hepatoblastoma. Emilia Chen, Christie English, Alejandro Allo Anido, Siân Hamer, Stefano Cairo, Alejandra Bruna. bioRxiv (2025).04.16.648783; doi: https://doi.org/10.1101/2025.04.16.648783

  3. KDM5-Driven Transcriptional Noise Fuels Plasticity-Led Awakening and Relapse in Paediatric Cancer. Alejandro Allo Anido, Cecilia Roux, Emilia Chen, Siân Hamer, Abigail Shea, Ayeh Sadat Sadr, Christie English, Charlotte Butterworth, Harvey Che, Angella Bellini, Birgit Geoerger, Gudrun Schleiermacher, Louis Chesler, Michael David Morgan, and Alejandra Bruna. bioRxiv (2025) doi:10.1101/2025.04.16.

Full list of publications

  1. El Laithy Y, Abreu De Oliveira WA, Pabba A, Qualizza A, Cosemans G, Garcia-Diaz P, Richard F, Athanasouli P, Rios Luci C, De Wispelaere W, Mourao L, Hamer S, Moens S, De Jaime-Soguero A, Baietti MF, Hutten SJ, Jonkers J, Sammut SJ, Soenen S, Scheele CL, Bruna A, Desmedt C, Annibali D, Lluis F. Chemotherapy-treated breast cancer cells activate the Wnt signaling pathway to enter a diapause-DTP state. Cancer Res. 2025. doi: 10.1158/0008-5472.CAN-24-4165.

  2. A Shea, Y Eyal-Lubling, D Guerrero-Romero, R Manzano Garcia , W Greenwood , M O’Reilly, D Georgopoulou, M Callari, G Lerda , S Wix , A Giovannetti, R Masina et al. ,Bruna (*co-last). Modelling drug responses and evolutionary dynamics using triple negative breast cancer patient-derived xenografts. Cancer Research 2024; doi: https://doi.org/10.1101/2023.01.10.523259

  3. Kreuzaler, P., Inglese, P., Ghanate, A. et al. Vitamin B5 supports MYC oncogenic metabolism and tumor progression in breast cancer. Nat Metab 5, 1870–1886 (2023). (Bruna #32 out of n=40) https://doi.org/10.1038/s42255-023-00915-7

  4. Cannell IG, Sawicka K, Pearsall I, Wild SA, Deighton L, Pearsall SM, Lerda G, Joud F, Khan S, Bruna A, Simpson KL, Mulvey CM, Nugent F, Qosaj F, Bressan D; CRUK IMAXT Grand Challenge Team; Dive C, Caldas C, Hannon GJ. FOXC2 promotes vasculogenic mimicry and resistance to anti-angiogenic therapy. Cell Rep. 2023 Aug 29;42(8):112791. doi: 10.1016/j.celrep.2023.112791.

  5. Ciscar M, Trinidad EM, Perez-Chacon G, Alsaleem M, Jimenez M, Jimenez-Santos MJ, Perez-Montoyo H, Sanz-Moreno A, Vethencourt A, Toss M, Petit A, (Bruna A #18 out of n=23). RANK is a poor prognosis marker and a therapeutic target in ER-negative postmenopausal breast cancer. EMBO Mol Med. 2023 Apr 11;15(4):e16715. doi: 10.15252/emmm.202216715.

  6. Wild SA, Cannell IG, Nicholls A, Kania K, Bressan D; CRUK IMAXT Grand Challenge Team (Bruna A as part of the CRUK IMAXT Grand Challenge Team); Hannon GJ, Sawicka K. Clonal transcriptomics identifies mechanisms of chemoresistance and empowers rational design of combination therapies. Elife. 2022 Dec 16;11:e80981. doi: 10.7554/eLife.80981.

  7. Dinami R, Pompili L, Petti E, Porru M, D'Angelo C, Di Vito S, Rizzo A, Campani V, De Rosa G, Bruna A, Serra V, Mano M, et al. MiR-182-3p targets TRF2 and impairs tumor growth of triple-negative breast cancer. EMBO Mol Med. 2023 Jan 11;15(1):e16033. doi: 10.15252/emmm.202216033.

  8. Funnell T, O'Flanagan CH, Williams MJ, McPherson A, McKinney S, Kabeer F, Lee H, Salehi S, Vázquez-García I, Shi H, Leventhal E, Masud T, Eirew P, Yap D, (Bruna A #49 part of the CRUK IMAXT Grand Challenge Team of 51 authors); Shah SP, Aparicio S. Single-cell genomic variation induced by mutational processes in cancer. Nature. 2022 Dec;612(7938):106-115. doi: 10.1038/s41586-022-05249-0.

  9. Palafox M, Monserrat L, Bellet M, Villacampa G, Gonzalez-Perez A, Oliveira M, Brasó-Maristany F, Ibrahimi N, Kannan S, Mina L, Herrera-Abreu MT, Òdena A, (Bruna A #16 out of 38). High p16 expression and heterozygous RB1 loss are biomarkers for CDK4/6 inhibitor resistance in ER(+) breast cancer. Nat Commun. 2022 Sep 7;13(1):5258. doi: 10.1038/s41467-022-32828-6.

  10. Serra V, Wang AT, Castroviejo-Bermejo M, Polanska UM, Palafox M, Herencia-Ropero A, Jones GN, Lai Z, Armenia J, Michopoulos F, Llop-Guevara A, Brough R et al. (Bruna A #20 out of 40). Identification of a Molecularly-Defined Subset of Breast and Ovarian Cancer Models that Respond to WEE1 or ATR Inhibition, Overcoming PARP Inhibitor Resistance. Clin Cancer Res. 2022 Oct 14;28(20):4536-4550. doi: 10.1158/1078-0432.CCR-22-0568.

  11. Abreu de Oliveira WA, El Laithy Y, Bruna A, Annibali D, Lluis F. Wnt Signaling in the Breast: From Development to Disease. Front Cell Dev Biol. 2022 May 18;10:884467. doi: 10.3389/fcell.2022.884467.

  12. Groelly FJ, Porru M, Zimmer J, Benainous H, De Visser Y, Kosova AA, Di Vito S, Serra V, Ryan A, Leonetti C, Bruna A, Biroccio A, Tarsounas M. Anti-tumoural activity of the G-quadruplex ligand pyridostatin against BRCA1/2-deficient tumours. EMBO Mol Med. 2022 Mar 7;14(3):e14501. doi: 10.15252/emmm.202114501.